NASDAQ:ONTX - Onconova Therapeutics Stock Price, Forecast & News

Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."

Shares of Onconova Therapeutics reverse split on the morning of Wednesday, September 26th 2018. The 1-15 reverse split was announced on Tuesday, September 25th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 25th 2018. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 7 shares after the split.

Onconova Therapeutics Inc (NASDAQ:ONTX) released its quarterly earnings data on Tuesday, August, 14th. The biopharmaceutical company reported ($1.05) EPS for the quarter, beating analysts' consensus estimates of ($1.20) by $0.15. The biopharmaceutical company had revenue of $0.49 million for the quarter, compared to analyst estimates of $0.52 million. Onconova Therapeutics had a negative return on equity of 872.01% and a negative net margin of 967.77%. View Onconova Therapeutics' Earnings History.

Onconova Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for Onconova Therapeutics.

3 brokers have issued 1 year target prices for Onconova Therapeutics' stock. Their forecasts range from $1.30 to $25.00. On average, they expect Onconova Therapeutics' share price to reach $11.43 in the next year. This suggests a possible upside of 2,622.2% from the stock's current price. View Analyst Price Targets for Onconova Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Onconova Therapeutics.

Headlines about ONTX stock have been trending very negative recently, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Onconova Therapeutics earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Onconova Therapeutics.

Some companies that are related to Onconova Therapeutics include MannKind (MNKD), Kamada (KMDA), AMAG Pharmaceuticals (AMAG), Gemphire Therapeutics (GEMP), Seres Therapeutics (MCRB), Bicycle Therapeutics (BCYC), BIOFRONTERA AG/ADR (BFRA), Kalvista Pharmaceuticals (KALV), VBI Vaccines (VBIV), IVERIC bio (ISEE), MEI Pharma (MEIP), Protagonist Therapeutics (PTGX), Ocular Therapeutix (OCUL), Sol Gel Technologies (SLGL) and Agile Therapeutics (AGRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), Progenics Pharmaceuticals (PGNX), SCYNEXIS (SCYX), Opko Health (OPK), Crispr Therapeutics (CRSP), FuelCell Energy (FCEL), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP) and vTv Therapeutics (VTVT).

Onconova Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.46%), Hillcrest Wealth Advisors NY LLC (0.18%) and UBS Group AG (0.07%). Company insiders that own Onconova Therapeutics stock include 683 Capital Management, Llc, Abraham N Oler, E Premkumar Reddy, Henry S Bienen, James J Marino, Mark Patrick Guerin, Michael B Hoffman, Steven M Fruchtman and Tyndall Capital Partners L P. View Institutional Ownership Trends for Onconova Therapeutics.

ONTX stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Hillcrest Wealth Advisors NY LLC and UBS Group AG. Company insiders that have bought Onconova Therapeutics stock in the last two years include 683 Capital Management, Llc, Abraham N Oler, E Premkumar Reddy, Henry S Bienen, James J Marino, Mark Patrick Guerin and Steven M Fruchtman. View Insider Buying and Selling for Onconova Therapeutics.

Shares of ONTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ONTX stock can currently be purchased for approximately $0.42.

Onconova Therapeutics has a market capitalization of $58.27 million and generates $1.23 million in revenue each year. The biopharmaceutical company earns $-20,570,000.00 in net income (profit) each year or ($4.99) on an earnings per share basis. Onconova Therapeutics employs 25 workers across the globe.View Additional Information About Onconova Therapeutics.

The official website for Onconova Therapeutics is http://www.onconova.com/.

Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The biopharmaceutical company can be reached via phone at 267-759-3680 or via email at [email protected]